STERIS (NYSE:STE – Get Free Report) updated its FY 2027 earnings guidance on Wednesday morning. The company provided EPS guidance of 11.000-11.300 for the period, compared to the consensus earnings per share estimate of 11.160. The company issued revenue guidance of $6.4 billion-$6.4 billion, compared to the consensus revenue estimate of $6.4 billion.
STERIS Trading Up 0.1%
NYSE:STE traded up $0.30 on Wednesday, reaching $233.15. The company’s stock had a trading volume of 923,106 shares, compared to its average volume of 739,470. STERIS has a 1-year low of $195.14 and a 1-year high of $269.44. The business’s 50-day moving average price is $214.04 and its two-hundred day moving average price is $225.66. The firm has a market cap of $22.72 billion, a PE ratio of 29.40 and a beta of 0.91. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.54 and a current ratio of 2.09.
STERIS (NYSE:STE – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.49 by $0.10. STERIS had a return on equity of 14.15% and a net margin of 13.18%.STERIS’s revenue was up 7.3% compared to the same quarter last year. During the same period last year, the firm posted $2.34 earnings per share. STERIS has set its FY 2027 guidance at 11.000-11.300 EPS. Equities research analysts anticipate that STERIS will post 11.17 earnings per share for the current fiscal year.
STERIS Increases Dividend
Analyst Upgrades and Downgrades
Several equities research analysts have commented on the stock. KeyCorp cut their price target on shares of STERIS from $291.00 to $269.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 13th. UBS Group started coverage on STERIS in a research report on Tuesday, July 28th. They issued a “buy” rating and a $275.00 target price on the stock. Weiss Ratings lowered STERIS from a “hold (c+)” rating to a “hold (c)” rating in a report on Wednesday, May 27th. Wall Street Zen lowered STERIS from a “buy” rating to a “hold” rating in a report on Saturday. Finally, Piper Sandler reissued an “overweight” rating and set a $270.00 price target on shares of STERIS in a research report on Thursday, May 21st. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, STERIS currently has an average rating of “Moderate Buy” and a consensus target price of $277.25.
Get Our Latest Stock Report on STE
Insider Activity at STERIS
In other STERIS news, VP John Adam Zangerle sold 1,419 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $209.28, for a total transaction of $296,968.32. Following the completion of the sale, the vice president owned 35,259 shares of the company’s stock, valued at $7,379,003.52. This trade represents a 3.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard C. Breeden sold 1,481 shares of STERIS stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $209.51, for a total transaction of $310,284.31. Following the transaction, the director directly owned 38,964 shares of the company’s stock, valued at approximately $8,163,347.64. This trade represents a 3.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 7,328 shares of company stock worth $1,554,051. Company insiders own 1.12% of the company’s stock.
STERIS News Roundup
Here are the key news stories impacting STERIS this week:
- Positive Sentiment: Earnings exceeded expectations: STERIS reported adjusted earnings of $2.59 per share, above the $2.49–$2.54 analyst consensus and up from $2.34 a year earlier. Revenue rose 7.3% year over year to approximately $1.5 billion. Steris Q1 Earnings Surpass Estimates
- Positive Sentiment: Broad-based operating growth: Healthcare revenue increased 8% to $1.05 billion, Applied Sterilization Technologies revenue rose 6% to $297.6 million, and Life Sciences revenue grew 9% to $146.7 million. Constant-currency organic revenue growth was 6%.
- Positive Sentiment: Growth investment supports longer-term prospects: STERIS plans to invest $600 million in a North Carolina formulated-chemistries manufacturing and distribution center to support sterilization and disinfection demand from healthcare and pharmaceutical customers. Steris to Invest in North Carolina Manufacturing Hub
- Neutral Sentiment: Fiscal 2027 outlook was maintained: The company reiterated revenue growth guidance of 7% to 8% and adjusted EPS guidance of $11.10 to $11.30, broadly in line with analyst expectations. Capital expenditures are expected to increase to approximately $450 million, while free-cash-flow guidance is about $800 million.
- Negative Sentiment: Near-term costs and cash-flow pressures: The North Carolina project and related restructuring are expected to generate approximately $55 million to $70 million in pretax charges over time. Operating cash flow declined to $367.1 million from $420.0 million in the prior-year quarter, while higher capital spending could weigh on near-term free cash flow.
- Negative Sentiment: Insider selling may temper sentiment: Company insiders reported five open-market sales and no purchases over the past six months, although these transactions are not necessarily tied to the quarterly results.
Institutional Investors Weigh In On STERIS
Institutional investors have recently made changes to their positions in the company. Jones Financial Companies Lllp boosted its stake in STERIS by 46.1% in the 1st quarter. Jones Financial Companies Lllp now owns 1,106 shares of the medical equipment provider’s stock valued at $251,000 after purchasing an additional 349 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of STERIS by 32.3% in the first quarter. Goldman Sachs Group Inc. now owns 242,732 shares of the medical equipment provider’s stock valued at $55,015,000 after acquiring an additional 59,264 shares during the period. Empowered Funds LLC grew its stake in shares of STERIS by 16.1% in the first quarter. Empowered Funds LLC now owns 2,303 shares of the medical equipment provider’s stock valued at $522,000 after acquiring an additional 319 shares in the last quarter. Woodline Partners LP grew its stake in shares of STERIS by 40.0% in the first quarter. Woodline Partners LP now owns 8,300 shares of the medical equipment provider’s stock valued at $1,881,000 after acquiring an additional 2,372 shares in the last quarter. Finally, Jane Street Group LLC raised its stake in STERIS by 38.9% in the 1st quarter. Jane Street Group LLC now owns 20,716 shares of the medical equipment provider’s stock worth $4,695,000 after purchasing an additional 5,803 shares in the last quarter. Institutional investors own 94.69% of the company’s stock.
About STERIS
STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.
Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.
Featured Stories
- Five stocks we like better than STERIS
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
- Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.
